36 results about "Carbamazepine" patented technology

The invention relates to a preparation method and application of a composite piezoelectric catalytic material NaNbO3-coated BiFeO3 for rapidly degrading antibiotics, NaNbO3 is flaky crystal grains with [001] crystallographic orientation prepared by a two-step molten salt method, and BiFeO3 is micro-nano particles prepared by a coprecipitation method. Composite micro-nano BiFeO3 powder and [001] oriented NaNbO3 flaky grains form a heterojunction, conversion of mechanical energy and electric energy of the material is achieved under the ultrasonic vibration condition, inductive charges are generated on the surface of the material, and photon-generated carriers move reversely under driving of a built-in electric field. According to the invention, the piezoelectric catalytic degradation capability of the BiFeO3 and NaNbO3 composite piezoelectric catalytic materials with different proportions on four antibiotics, namely oxytetracycline, levofloxacin, carbamazepine and paracetamol in different time periods is researched. When the mass ratio of the BiFeO3 to the NaNbO3 composite material is 1: 3, the oxytetracycline degradation rate within 30 min can reach 78.2%, the oxytetracycline degradation rate within 120 min can reach 91.8%, and the piezoelectric electro-catalysis characteristic is rapid and efficient. The method disclosed by the invention has important significance in developing a high-efficiency piezoelectric catalyst for degrading antibiotics.

The invention relates to application of iron-doped carbon nitride rich in nitrogen vacancies, in particular to application of the iron-doped carbon nitride rich in the nitrogen vacancies in degradation of active pharmaceutical compounds based on a degradation system of UV-LED / NaClO and / or UV-LED / NH2Cl. The removal rates of the UV-LED / NaClO / Fe-g-C3N4-Nv degradation system and the UV-LED / NH2Cl / Fe-g-C3N4-Nv degradation system on carbamazepine are as high as 98.3% and 67.2% respectively, the oxidation capacity of g-C3N4 is enhanced through iron doping, a new intermediate energy level is formed through introduction of nitrogen vacancy, the effect of an electron capturer is achieved, a new electron transmission channel is formed under the combined action of iron doping and nitrogen vacancy, and the degradation efficiency of carbamazepine is improved. The migration rate of electrons and the separation efficiency of photon-generated carriers are obviously improved; meanwhile, the Fe-g-C3N4-Nv achieves efficient activation of NaClO and NH2Cl through O2.-and hvb + under UV-LED irradiation, the yield of HO., RCS and RNS in a degradation system is increased, the adaptability to water quality fluctuation is high, and stable degradation of pharmaceutical active compounds can be achieved.

The invention discloses a carbamazepine and disodium glycyrrhizinate co-amorphous compound and a preparation method of the carbamazepine and disodium glycyrrhizinate co-amorphous compound. The co-amorphous compound is a single-phase amorphous mixture prepared from carbamazepine and disodium glycyrrhizinate. The composition can be prepared by adopting a spray drying method. The thermodynamic property of the carbamazepine and disodium glycyrrhizinate co-amorphous compound is verified through DSC, and it is shown that a co-amorphous system is formed. The dissolution rate of the carbamazepine and disodium glycyrrhizinate co-amorphous compound is obviously superior to that of a single crystal medicine and a physical mixture thereof, and the carbamazepine and disodium glycyrrhizinate co-amorphous compound shows excellent physical stability and has the potential of improving the bioavailability of carbamazepine. Meanwhile, the preparation method is simple to operate, the use of an auxiliary material carrier is omitted, and a new preparation thought is provided for the drug combination of other insoluble compounds.

Described herein, inter alia, are compositions comprising and methods of making and using endothelial cells (ECs) comprising one or more mitophagy-inducing agents (e.g., rapamycin, SKF-96365, lithium, carbamazepine, latrepirdine, spermidine, resveratrol, sodium valproate, trehalose, kaempferol, metformin, AICAR, nilotinib, ambroxol, curcumin, and VL-004). Also described herein, inter alia, are methods vascular cell therapy, promoting blood vessel formation, and increasing vascular development, angiogenesis, and cell junction via administration of a population of ECs comprising a mitophagy-inducing agent (MIA-ECs).

The present invention provides the use of phenylquinolinone and flavonoid derivatives for neuropathic pain, and the phenylquinolinone and flavonoid derivatives include pharmaceutically acceptable salts thereof. The compound of the present invention is a histamine H3 receptor antagonist, which has a different mechanism of action from existing drugs and can be used in the preparation of drugs for treating neuropathic pain diseases. The effect of the compound of the present invention in treating neuropathic pain is better than amitriptyline, gabapentin, pregabalin and carbamazepine, indicating that the compound of the present invention has a better therapeutic effect, has the characteristics of small dosage, good efficacy, high bioavailability and safety, and compared with opioid drugs, the compound of the present invention is not addictive and is a very effective drug for treating neuropathic pain diseases. Therefore, the clinical application prospects are huge. The general structural formula is as follows:

The utility model discloses an ethanol purifying and recycling device in a carbamazepine ammonification process, and belongs to the technical field of chemical production equipment. The device comprises a rectification and purification device, a reflux control device connected with the rectification and purification device, and a molecular sieve dryer used for ethanol recycling, and the rectification and purification device comprises a supergravity bed used for rectification and purification, a reboiler and a condenser. The backflow control device comprises a main conveying pipe connected to the condenser, a first branch conveying pipe and a second branch conveying pipe, wherein the first branch conveying pipe and the second branch conveying pipe are arranged at the end of the main conveying pipe. According to the utility model, the rectification recovery of ethanol is realized through the supergravity bed, the reboiler and the condenser, and the reflux ratio is controlled through the reflux control device, so that the purity and the recovery efficiency of the recovered ethanol are improved; ethanol in the collecting tank after rectification is dried through the molecular sieve dryer, absolute ethanol is obtained, and the crude carbamazepine product is subjected to secondary refining, so that the ethanol in the carbamazepine ammoniation process is recycled with the advantages of industrial production, simple process and low energy consumption.

The application discloses application of a eutectic solvent in improving solubility of carbamazepine, wherein the eutectic solvent is prepared by taking castor oil acid or 1,2-propanediol as a hydrogen bond donor, taking menthol or glycerol as a hydrogen bond acceptor, and the molar ratio of the hydrogen bond acceptor to the hydrogen bond donor being 1-7:1-3. The activity coefficient prediction module of the COSMO-RS model is used to screen a suitable hydrogen bond acceptor (HBA) and a hydrogen bond donor (HBD) to construct a eutectic solvent DESs system, so that the problem of low efficiency of a traditional trial-and-error method is solved, and a low-cost and green eutectic solvent DESs is successfully prepared through further systematic optimization. The solubility experiment data show that the prepared DESs can significantly improve the solubility of carbamazepine, and a new way is provided for development of a carbamazepine preparation.

The present invention relates to the field of environmental pollution control, and discloses the application of a molybdenum trisulfide catalyst in the piezoelectric catalytic removal of carbamazepine, wherein the molybdenum trisulfide catalyst is obtained by stirring a mixed solution of molybdenum trioxide, a sulfide salt and water at a high speed and slowly adding acid until a large amount of gaseous hydrogen sulfide is produced, and drying to obtain a black solid. The molybdenum trisulfide catalyst is used to self-supply hydrogen peroxide under piezoelectric conditions and activate hydrogen peroxide to produce active substances, which can greatly improve the efficiency of removing carbamazepine in water bodies, and the removal rate can be as high as 99.3%, and the toxicity is reduced in the process of removing carbamazepine. In addition, the catalyst of the present invention can be recycled and easily recovered after the reaction, and will not cause pollution to the water environment.

The invention relates to a method for removing carbamazepine in water by using vacuum ultraviolet activated ferrate, aiming at solving the problems that the ferrate is weak in capability of oxidizing carbamazepine under neutral and alkaline conditions and the utilization rate of the capability of oxidizing pollutants is low when the ferrate and a strong complex coexist, and the like. The method for removing carbamazepine in water comprises the following steps: 1, adjusting the pH value of wastewater containing carbamazepine to 7-9; 2, putting a vacuum ultraviolet lamp into a glass cover, and then immersing the glass cover into the wastewater of which the pH value is adjusted; and 3, adding ferrate into the wastewater of which the pH value is adjusted, carrying out radiation trigger reaction on the wastewater of which the pH value is adjusted by virtue of a preheated vacuum ultraviolet lamp, and simultaneously carrying out stirring reaction, so that the degradation of carbamazepine in the water is realized. According to the method, vacuum ultraviolet is combined with a ferrate oxidation technology, intermediate-state iron substances and hydroxyl free radicals generated in a system are used for rapidly degrading carbamazepine in water, and the removal rate of carbamazepine in water reaches 90% or above.

The invention discloses a novel process for continuously preparing carbamazepine, which comprises the following steps: (1) dissolving indole in an organic solvent as a raw material solution I, filling a tubular reactor with a copper catalyst and the like, reacting the raw material solution I in the tubular reactor to obtain a reaction solution, and distilling to obtain 1-phenylindole; (2) respectively dissolving 1-phenylindole and an acid catalyst in an organic solvent to serve as a raw material solution II and a raw material solution III, mixing the raw material solution II and the raw material solution III through a tubular reactor for reaction to obtain a reaction solution, and recrystallizing the reaction solution to obtain iminostilbene; and (3) dissolving iminostilbene and triphosgene in an organic solvent to serve as raw material solutions IV and V, carrying out mixed reaction on the raw material solutions IV and V through a tubular reactor, carrying out mixed reaction with ammonia water again after the reaction is ended, and finally recrystallizing the reaction solution to obtain carbamazepine. The process comprises three steps of reaction, the yield of each step is more than 85%, the reaction speed is high, the side reaction is few, the mass and heat transfer efficiency is high, the safety is high, the three wastes are few, the cost is low, and the post-treatment is convenient.

The present invention provides a guidance method and a kit for personalized drug use of carbamazepine. Specifically, the present invention takes into account the differences in the efficacy of drugs used by different epilepsy patients, screens out a combination of SNP sites of genes related to personalized drug use of carbamazepine, and uses a nucleic acid mass spectrometer to perform extensive (high-throughput detection sites, high-throughput detection samples) screening and testing of genetic markers related to carbamazepine. The method of the present invention has a high detection success rate, good technical reproducibility, and high cost performance, and can realize the detection of multiple genes in a single small sample, meeting the maximum use of small samples; the method of the present invention has the technical advantages of high accuracy and high sensitivity, and the detection results are stable, which improves the detection positive rate.

The invention provides a carbamazepine pharmaceutical composition as well as a preparation method and application thereof, and belongs to the field of medicine preparation. The carbamazepine pharmaceutical composition provided by the invention comprises carbamazepine, a filler, an adhesive, a disintegrating agent and a lubricant, wherein the filling agent comprises microcrystalline cellulose, the disintegrating agent comprises low-substituted hydroxy propyl cellulose and carbamazepine, and the mass ratio of the microcrystalline cellulose to the low-substituted hydroxy propyl cellulose is 1: (2.795-2.895): (0.18-0.28). According to the carbamazepine pharmaceutical composition, the content uniformity of the medicine can be improved, the dissolution rate of a self-developed preparation is consistent with that of a reference preparation under the condition that the same specification is guaranteed, it is guaranteed that tabletting is smooth in the production process, and the carbamazepine pharmaceutical composition has actual clinical application value.

The present application relates to a kind of methods for degrading carbamazepine by sodium periodate catalysis driven by ultraviolet light.To the water to be treated containing carbamazepine,1.0mM sodium periodate is added, and irradiated by ultraviolet light with excitation wavelength of 254nm, so as to degrade carbamazepine.Using sodium periodate oxidation alone, ultraviolet photolysis is almost ineffective for degrading carbamazepine, and the combination of sodium periodate and ultraviolet light can effectively degrade carbamazepine. The present application further studies the intermediate product of degrading carbamazepine by sodium periodate catalysis driven by ultraviolet light, and obtains 7 degradation intermediates, which can be used for detecting or evaluating the degradation degree, degradation speed and residual pollution of carbamazepine. The degradation experiment of carbamazepine in actual water body shows that the method of the present application has good stability and is less affected by environmental factors.

The invention relates to application of an activating agent in promotion of uranium element discharge. Specifically, the activating agent is prepared from rifampicin, erythromycin, progesterone, aldosterone, bilirubin, cholate vinblastine, doxomicin, adriamycin, paclitaxel, bosentan, ambrisentan, digoxin, verapamil, tonavir, amprenavir, indinavir, hypericum perforatum juice, curcumin, atorvastatin beclomethasone, budesonide, divaricasone carbamazepine and caffeine. And phenytoin. The use dosage of the activating agent is 10 to 60 mg / kg. According to the method, the accumulation amount of uranium in important organs such as bones and kidneys can be remarkably reduced, so that the potential toxic influence on the key organs is reduced.

This application relates to the field of analytical detection technology, specifically to sample pretreatment methods, kits, and detection methods for the detection of antiepileptic drugs. The sample pretreatment method for the detection of antiepileptic drugs in this application includes one or more of the following antiepileptic drugs: valproic acid, carbamazepine, phenytoin, levetiracetam, lamotrigine, and phenobarbital. The sample pretreatment method includes the following steps: mixing magnetic beads with an activation solution to prepare a magnetic bead suspension; mixing the sample to be tested, the magnetic bead suspension, and an internal standard solution, and separating the supernatant and the magnetic bead complex after magnetic adsorption treatment; adding an eluent to the magnetic bead complex, and collecting the magnetic bead-target complex after elution treatment; adding an elution buffer to the magnetic bead-target complex, and collecting the supernatant after elution treatment for detection. The above sample pretreatment method is simple to operate, time-saving, and low-cost, providing key technical support for the efficient quantitative detection of antiepileptic drugs.

Wastewater treatments and facilities are provided that utilize a seed reactor and a granular activated carbon system to facilitate and enhance the removal of specific low molecular weight compounds that are slowly biodegradable, including the four compounds required for direct potable reuse chemical compliance. More specifically, the wastewater treatments and facilities described herein can obtain at least a 1-log (90 percent) removal of low molecular weight compounds, such as acetone, formaldehyde, carbamazepine, and sulfamethoxazole, from wastewater streams.

The utility model relates to a synthetic reaction device suitable for carbamazepine bromide. The synthetic reaction device comprises a reaction kettle, a solid feeder, a condenser, a solvent receiving tank, a buffer tank and a pipeline system, the reaction kettle, the solid feeder, the solvent receiving tank and the buffer tank are provided with discharging pipes and control valves, the pipeline system is properly provided with a control valve, two working modes of backflow gas absorption and evaporation solvent gas absorption are switched through a valve switch, and the solid feeder can slowly add solids into a reaction system. According to the utility model, the feeding speed of solid materials can be controlled, and two working modes of reflux gas absorption and evaporation solvent gas absorption can be quickly and conveniently switched.

The application provides a carbamazepine supramolecular hydrogel and a preparation method, a characterization method and an application thereof. The carbamazepine supramolecular hydrogel is prepared by using Fmoc group modified phenylalanine dipeptide molecules and carbamazepine molecules as raw materials, organic solvents and water as solvents, and has the advantages of simple preparation method, good biocompatibility, crystal form conversion of carbamazepine into amorphous, and slow release of carbamazepine. The infrared spectrum analysis method is used to monitor the change process in situ and in real time, to explore the structure change of the carbamazepine crystal, and to explore the intermolecular interaction mechanism of the peptide-based supramolecular gel on the crystal form conversion, so as to provide a theoretical basis for the structure-activity relationship of the drug.

Wastewater treatments and facilities are provided that utilize a seed reactor and a granular activated carbon system to facilitate and enhance the removal of specific low molecular weight compounds that are slowly biodegradable, including the four compounds required for direct potable reuse chemical compliance. More specifically, the wastewater treatments and facilities described herein can obtain at least a 1-log (90 percent) removal of low molecular weight compounds, such as acetone, formaldehyde, carbamazepine, and sulfamethoxazole, from wastewater streams.

The application discloses a new process for continuously preparing carbamazepine, and comprises the following steps: (1) dissolving indole in an organic solvent as raw material liquid I, filling a copper catalyst and the like in a tubular reactor, and reacting the raw material liquid I through the tubular reactor to obtain a reaction liquid, and distilling the reaction liquid to obtain 1-phenylindole; (2) dissolving 1-phenylindole and an acid catalyst in organic solvents respectively as raw material liquids II and III, mixing and reacting the raw material liquids II and III through a tubular reactor to obtain a reaction liquid, and recrystallizing the reaction liquid to obtain imino stilbene; (3) dissolving imino stilbene and triphosgene in organic solvents as raw material liquids IV and V, mixing and reacting the raw material liquids IV and V through a tubular reactor, mixing and reacting the reaction liquid with ammonia water again, and finally recrystallizing the reaction liquid to obtain carbamazepine; the process has three steps of reaction in total, the yield of each step is above 85%, the reaction speed is fast, the side reaction is less, the mass transfer and heat transfer efficiency is high, the safety is high, the waste is less, the cost is low, and the post-treatment is convenient.

The invention relates to the technical field of biological medicines, in particular to application of a CCR1 / 5 inhibitor Met-RANTES in inhibition of pathological pain of trigeminal nerves. According to the invention, CCR1 / 5 is taken as a therapeutic target of chronic pain, and a medicine which is remarkable in analgesic effect, small in side effect and capable of relieving chronic pain and improving pain mood is developed by combining the pharmacological function of an inhibitor Met-RANTES of CCR1 / 5. The Met-RANTES inhibits a central nervous system chemokine receptor CCRR1 / 5 in a targeted manner in a regular nasal administration manner, so that pathological mechanical pain-sensitive response and accompanying negative emotion caused by chronic compression of trigeminal nerves can be remarkably relieved, and pain feeling is relieved. In addition, the analgesic effect of the drug combination of the Met-RANTES and the carbamazepine is more obvious than that of the drug combination of the Met-RANTES and the carbamazepine which are independently used. The nasal delivery mode enables the medicine to directly reach the central nervous system, and reduces side effects of the whole body.

The invention relates to the technical field of analysis and detection, in particular to a sample pretreatment method for anti-epileptic drug detection, a kit and a detection method. According to the sample pretreatment method for anti-epileptic drug detection, an anti-epileptic drug comprises one or more of valproic acid, carbamazepine, phenytoin, levetiracetam, lamotrigine and phenobarbital; the sample pretreatment method comprises the following steps: mixing magnetic beads with an activating solution to prepare a magnetic bead suspension; mixing a to-be-detected sample, the magnetic bead suspension and the internal standard solution, performing magnetic attraction treatment, and separating supernate and a magnetic bead compound; leacheate is added into the magnetic bead compound, and after leaching treatment, a magnetic bead-target compound is collected; and adding an eluent into the magnetic bead-target compound, carrying out elution treatment, and collecting a supernatant for detection. The sample pretreatment method is simple to operate, short in time consumption and low in cost, and can provide key technical support for efficient quantitative detection of the anti-epileptic drugs.

The utility model discloses a carbamazepine quantitative determination kit, and particularly relates to the technical field of kits, the carbamazepine quantitative determination kit comprises a box body, a plurality of assembly seats and a sealing cover, the bottoms of the assembly seats are in bolted connection with the bottom of the box body, a pipe body and a control assembly used for stabilizing the pipe body are arranged in a top storage groove, the pipe body slides down along an inclined plane and contacts and extrudes a positioning plate, and the positioning plate is fixed on the box body. After the rotating roller overcomes the torque force of the coil spring to rotate, the moving seat slides along the wall of the mounting groove, the coil spring is stretched to store energy and the pipe body is placed in place, the coil spring releases elastic potential energy, so that the rotating roller rotates reversely to drive the moving seat and the positioning plate to move towards the center of the storage groove, and the positioning plate and the rubber strip are tightly attached to the pipe body; the pipe body is fixed, the stability is good, shaking, collision and damage of the pipe body and reagent leakage in the transportation and use process can be avoided, safety and accuracy are guaranteed, the structure is flexible, stress is uniform, the pipe body can be conveniently placed in and taken out only by overcoming certain external force, and maintenance and replacement are facilitated through the split type design.

The invention is applicable to the technical field of drug-loaded polymer medical preparations, and provides a carbamazepine-based transdermal patch and a preparation method thereof, and the carbamazepine-based transdermal patch comprises a drug-containing layer, a backing layer and a protective layer; the active ingredient of the medicine-containing layer is carbamazepine or pharmaceutically acceptable salt thereof, and the content of carbamazepine or pharmaceutically acceptable salt accounts for 5-35% of the total mass of the medicine-containing layer; the matrix of the drug-containing layer is composed of one or more of polyvinyl alcohol, acrylic acid pressure-sensitive adhesive, polybutylene pressure-sensitive adhesive and polysiloxane pressure-sensitive adhesive, and the content of the matrix accounts for 50%-80% of the total mass of the drug-containing layer. The transdermal patch prepared by the invention can last for 1-5 days, has a continuous and stable transdermal effect and good safety, effectively improves the compliance and convenience of a patient, and can be used for diminishing inflammation and easing pain caused by osteoarthritis, muscle pain and trauma.

The invention relates to the technical field of experimental animal model construction methods and anti-environmental factor related epilepsy drug screening, in particular to an epilepsy animal model construction method and a drug obtained through model screening and used for treating epilepsy. The invention discloses a construction method of an epilepsy animal model. The epilepsy animal model is a zebra fish model of epilepsy caused by permethrin exposure. The zebrafish embryo is soaked in permethrin environment for a certain time, and the epilepsy animal model can be obtained. The model can be used for researching the effect of environmental factors in the occurrence and development of epilepsy. The medicine screened by the animal model comprises at least one of topiramate, sodium valproate, carbamazepine, methocarbamol, flecainib acetate, SYM2206, D-AP5, CNQX and baclofen. According to the technical scheme, the technical problem that an epilepsy animal model related to environmental factors is lacked in the prior art can be solved, and the method has ideal application and popularization value.

The invention discloses carbamazepine compressed solid tablet granulation equipment, and particularly relates to the technical field of granulation, the carbamazepine compressed solid tablet granulation equipment mainly comprises a granulation box, an electric cylinder and a linkage block, the electric cylinder is fixed in front of the granulation box, the linkage block is fixed on the output end of the electric cylinder, and the bottom end of the linkage block is provided with a linkage adjusting mechanism; the linkage adjusting mechanism comprises a linkage strip fixedly installed at the bottom end of the linkage block, two connecting blocks are welded to the bottom end of the linkage strip, and the bottom end of each connecting block is fixedly connected with a shaft ring. The linkage adjusting mechanism and the electric cylinder push the linkage block to move, the linkage block drives the linkage strip to move and move forwards, the two connecting blocks can drive the two shaft rings to move forwards synchronously, the two linkage barrels can achieve sliding adjusting operation synchronously, the thickness of the granulation holes is adjusted according to needs, and the granulation efficiency is improved. And aiming at carbamazepine compressed solid tablet particles with different thicknesses, the granulating operation is realized, and the granulating applicability is wider.

The utility model discloses a carbamazepine bromination process ethanol recovery device based on a rectifying still, and belongs to the technical field of chemical medicine recovery. The device comprises a preheating device, a rectification device, a steam temporary storage device and a heat exchange device, wherein the preheating device is arranged on a guide pipe on one side of the rectification device; the steam temporary storage device is arranged at the tail end of a steam pipe at the top end of the rectification device; the heat exchange device is connected to the lower portion of the steam temporary storage device through a guide pipe. On the basis that ethanol is obtained through rectification and purification of traditional equipment, heat brought by ethanol steam is guided into the preheating device again through the heat exchange device, ethanol mixed waste liquid is heated preliminarily, efficient recycling of the heat is achieved, and the operation cost of the whole equipment is reduced to a great extent.

The present invention provides a synthesis method for a substituted iminostilbene compound. When the substituent is hydrogen, the substituted iminostilbene compound is an iminostilbene compound and is a carbamazepine intermediate. A preparation method provided by the present invention comprises the following steps: (1) performing coupling reaction on indole and halobenzene under the action of alkali and a solvent to obtain 1-phenylindole; (2) carrying out rearrangement reaction on the 1-phenylindole under the action of a catalyst and protonic acid to obtain iminostilbene; and (3) carrying out substitution reaction on iminostilbene and chlorosulfonyl isocyanate to obtain carbamazepine. The present invention has the characteristics of high yield, short reaction time, less waste water, waste gas and solid wastes, low costs, and a simple process, and is suitable for industrial production.

The present application relates to a kind of drug raw materials and its preparation method and characterization method, specifically related to a kind of carbamazepine-succinic acid co-crystal (CBZ-SA) and its preparation method and terahertz spectroscopy characterization test method.The purpose of the present application is to solve the problem that the position and number of hydrogen bond in the existing carbamazepine-succinic acid co-crystal are uncertain, and the precision of X-ray diffraction method for characterizing carbamazepine-succinic acid co-crystal is not enough, and the steps are complex.The present application provides a preparation method for carbamazepine-succinic acid co-crystal, which is wet grinding method using ethanol, then the terahertz spectroscopy experimental system is used to characterize carbamazepine-succinic acid co-crystal, the terahertz absorption spectrum of CBZ-SA co-crystal is obtained, and the spectrum result obtained can not only prove the result difference of different preparation methods, but also be used as subsequent CBZ-SA prediction structure simulation absorption spectrum for contrast verification, to verify the correctness of CBZ-SA co-crystal prediction structure.

The invention discloses a synthesis method of carbamazepine and analogues thereof, which comprises the following steps of: dispersing a dibenzo [b, f] azepine analogue shown in a formula (I), a photocatalyst and a metal cobalt complex in an organic solvent under an illumination condition, and carrying out dehydrogenation reaction under illumination with a certain wavelength. And after the reaction is finished, carrying out post-treatment on the reaction liquid to obtain carbamazepine and the analogue thereof as shown in the formula (II). The reaction formula is as follows. The synthesis of carbamazepine and the analogue thereof is realized by taking a light source as a reaction energy source, so that the reaction is safer and more environment-friendly, and the cost is lower.